626-P: Intermittently Scanned Continuous Glucose Monitoring Data of Polish Patients from Real-Life Conditions: More Scanning and Better Glycemic Control than Worldwide

Abstract

Randomized trials and observational studies have shown that the use of FreeStyle Libre® intermittently-scanned CGMS was associated with improved glycemic indices such as HbA1c, TIR (70-180 mg/dl), TBR (<70 mg/dl) or TAR (>180 mg/dl), and improved quality of life. In this RWD analysis, we aimed to describe glucometrics among FreeStyle Libre users from Poland and compare them with international data. The analyzed time period for the Polish and worldwide users ranged from August 2016, September 2014, respectively, to August 2020. Data from the Polish population was collected from 10,679 readers and 92,627 sensors with 22.3 million glucose scans and 113 million automatically-recorded glucose readings, while the worldwide database included information from 981,876 readers and 11,179,229 sensors with 13.1 billion glucose readings. On average, the Polish users of isCGM performed substantially more scans/day (21.2±14.2 vs. 13.2±10.7), were characterized by considerably lower eHbA1c (7.0±1.2% vs. 7.5±1.5%), spent more TIR (64.2±17.3% vs. 58.1±20.3%) and less TAR (29.7±18.0% vs. 36.6±21.3%) (p<0.0001 for all comparisons). Moreover, Polish users were more likely to achieve TIR>70% (36.3% vs. 28.8%). Our results confirmed earlier findings that analyzed glucometrics improve as scan rate frequency increases; however, additional analyses showed that at the same scanning frequency, Polish users achieved lower eHbA1c, higher TIR, lower TAR, but higher TBR than the comparative group. In summary, we report more scanning and better glycemic control in Polish isCGM users than worldwide. Due to the nature of this study, we are not able to explain the cause of this observation. It could be associated with demographic characteristics, such as a higher proportion of adult users, or more efficient diabetes education. Our data seems to suggest more frequent scanning than currently recommended. Disclosure J. Hohendorff: Advisory Panel; Self; Abbott, Roche Diabetes Care, Other Relationship; Self; Merck & Co., Inc., Polfa Tarchomin S. A. J. Gumprecht: Advisory Panel; Self; Abbott, Research Support; Self; Bayer AG, Merck & Co., Inc., Speaker’s Bureau; Self; AstraZeneca, Bioton S. A., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, MSD Corporation, Novo Nordisk A/S, Sanofi. M. Mysliwiec: None. D. Zozulinska-ziolkiewicz: None. M. Malecki: Advisory Panel; Self; Abbott Diabetes, Medtronic, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Merck & Co., Inc., Mundipharma International, Novo Nordisk, Sanofi-Aventis, Servier Laboratories.